ESMO 2019 | Molecular target therapy in pancreatic and liver cancer

Hani Babiker • 18 Oct 2019

Gastrointestinal Cancer Liver Cancer Pancreatic Cancer Atezolizumab Bevacizumab Lenvatinib Olaparib Pembrolizumab

Hani Babiker, MD, The University of Arizona, Tucson, AZ, talks about various updates in the fields of pancreatic and liver cancer, with a focus on molecular-based target therapies. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

A promising future for drug development in gastrointestinal cancer

Hani Babiker • 29 Nov 2018

Current trials in colorectal cancer investigating panitumumab

Hani Babiker • 29 Nov 2018

Cemiplimab prospects: CRC, CSCC & HNSCC

Hani Babiker • 29 Nov 2018

ILLUMINATE 101: Updates and implications on colorectal cancer

Hani Babiker • 18 Oct 2019

Related Videos

Impact of COVID-19 on HCC management

Bruno Sangro • 1 Jul 2020

Pancreatic cancer: moving forward

Michel Ducreux • 1 Oct 2019

Ad-CEA vaccine plus avelumab vs mFOLFOX6-based standard care in untreated metastatic CRC

Jason Redman • 3 Jul 2020

Current therapies for advanced HCC and their limitations

Michael Pishvaian • 16 Nov 2018